Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study
Autor: | Su Ching Yang, Chia Tse Weng, Chien Yao Sun, Chun Hsin Wu, Chun Yu Lin, Hung An Chen, Tsai-Ching Hsu |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty lcsh:Diseases of the musculoskeletal system National Health Programs Hypertension Pulmonary Population Taiwan Comorbidity Kaplan-Meier Estimate Pulmonary arterial hypertension Cohort Studies 03 medical and health sciences 0302 clinical medicine Systemic lupus erythematosus immune system diseases Internal medicine polycyclic compounds Medicine Humans Lupus Erythematosus Systemic Cumulative incidence Risk factor education skin and connective tissue diseases Survival rate Aged Proportional Hazards Models 030203 arthritis & rheumatology education.field_of_study business.industry Incidence (epidemiology) Incidence Hazard ratio Middle Aged Prognosis Confidence interval Survival Rate 030104 developmental biology Population Surveillance Female lcsh:RC925-935 business Cohort study Research Article |
Zdroj: | Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-8 (2019) Arthritis Research & Therapy |
ISSN: | 1478-6362 |
Popis: | Background No population-based study has investigated the cumulative incidence of pulmonary arterial hypertension (PAH) in patients with newly diagnosed systemic lupus erythematosus (SLE) or the survival impact of PAH in this population. Method We used a nationwide database in Taiwan and enrolled incident SLE patients between January 1, 2000, and December 31, 2013. The cumulative incidence of PAH in the SLE patients and the survival of these patients were estimated by the Kaplan-Meier method. Potential predictors of the development of PAH were determined using a Cox proportional hazards regression model. Results Of 15,783 SLE patients, 336 (2.13%) developed PAH. The average interval from SLE diagnosis to PAH diagnosis was 3.66 years (standard deviation [SD] 3.36, range 0.1 to 13.0 years). Seventy percent of the patients developed PAH within 5 years after SLE onset. The 3- and 5-year cumulative incidence of PAH were 1.2% and 1.8%, respectively. Systemic hypertension was an independent predictor of PAH occurrence among the SLE patients (adjusted hazard ratio 2.27, 95% confidence interval 1.59–2.97). The 1-, 3-, and 5-year survival rates of SLE patients following the diagnosis of PAH were 87.7%, 76.8%, and 70.1%, respectively. Conclusions PAH is a rare complication of SLE and the majority of PAH cases occur within the first 5 years following SLE diagnosis. Systemic hypertension may be a risk factor for PAH development in the SLE population. The overall 5-year survival rate after PAH diagnosis was 70.1%. |
Databáze: | OpenAIRE |
Externí odkaz: |